- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Diabetes Leader USV slashes price of its popular Diabetes Medicine JALRA OD
Overview
Mumbai: With an aim to make its popular antidiabetic medicine more affordable and accessible to the Indian population, leading pharma company USV Ltd. has now reduced the price of its brand Jalra-OD.
The once daily dosing tablet of JALRA OD which contains Vildagliptin 100mg SR will now be available at price of Rs 13.5 per tablet a sharp reduction from its earlier price of Rs 18 per tablet.
Jalra-OD is the No.1 prescribed brand as per data from healthplix and is trusted by more than 50 thousand patients. Jalra-OD which contains Vildagliptin 100mg SR is a well studied molecule with 90% DPP4 inhibition while the DPP4 inhibition by Sita 100mg is 86.9%. Along with being efficacious Vildagliptin 100mg SR has proven its hepatic and cardiac safety.
Reference: Herman GA, et al. Clinical Pharmacology & Therapeutics. 2005; 78(6):675-88.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)